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Background: Mediator complex subunit 19 (Med19) is a critical subunit of the mediator complex that forms a
bridge between the transcription factors and RNA polymerase II. Although it has been reported that Med19 plays
an important role in stabilizing the whole mediator complex, its biological importance in tongue cancer cell
proliferation and migration has not been addressed.
Methods: By using MTT, BrdU incorporation, colony formation, flow cytometric, tumorigenesis and transwell assays,
We tested the Med19 role on tongue cancer cell growth and migration.
Results: We demonstrated that lentivirus-mediated Med19 knockdown could arrest tongue cancer cells at G1
phase, inhibit tongue cancer cell proliferation and migration in vitro. The tumorigenicity of Med19 short hairpin RNA
(shRNA)-expressing lentivirus infected tongue cancer cells were decreased after inoculating into nude mice.
Conclusions: These results indicate that Med19 plays an important role in tongue cancer proliferation and
migration, and suggest possible applications for tongue cancer therapy.
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Oral squamous cell carcinoma represents the sixth most
common cancer around the world [1], and tongue car-
cinoma is one of the most common types of oral cancer
[2]. Similar to other malignancies, the formation of
tongue carcinoma is a complex process associated with
accumulation of genetic and epigenetic changes that
occur during the progression of the disease. Understand-
ing the molecular mechanisms underlying tongue car-
cinoma progression may provide unique strategies for
the development of molecular-targeted therapies for pre-
vention and treatment of tongue carcinoma. The Me-
diator complex is a large multiprotein complex which is
vital for transcriptional regulation and controls cell pro-
liferation and differentiation [3]. It is expressed ubiqui-
tously and conserved from yeast to mammals [4]. In
yeast, Mediator is composed of 25 subunits, and divided* Correspondence: guiqingliao@126.com
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reproduction in any medium, provided the orinto three discrete domains: the head, middle, and tail
modules [5-7]. Med19 (ROX3) [Ensembl: ENSG00
000156603.10] was first identified during a screen for
mutants with increased expression of the heme-
regulated CYC7 gene and proposed to be an transcrip-
tional regulator because of its nuclear localization [4].
The hypothesis of Med19 (ROX3) as a transcriptional
regulator was further confirmed in a gene expression
microarray study in Med19 deletion strain because a
broad range of genes was found to be up- or down-
regulated after Med19 functional disruption. Further-
more, Med19 has been demonstrated to be a component
of the Mediator complex [8] and is essential for me-
diator binding and its activation of RNA Pol II [9,10].
Structural analysis showed that Med19 is involved in
head-module subunits in mammalian mediator complex
and plays an important role in the whole mediator
stabilization.
The potent function of Med19 as a transcription
coactivator for regulating gene expression pattern sug-
gests its role in the development of malignancies.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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feration of bladder cancer, hepatocellular carcinomas,
prostate cancer, gastric cancer and breast cancer cells
[11-15]. However, the functional role of Med19 in
tongue cancer cell growth and migration has not been
reported.
In the present study, we constructed recombinant
lentivirus delivering short hairpin RNA (shRNA)
against Med19, which expresses GFP as a marker. The
effect of Med19 silencing in tongue cancer cell prolifer-
ation, tumor formation and cell migration was investi-
gated in vitro and in vivo. Our investigation may gain
more insights into the progression of tongue cancer
and provide a new target for gene therapy for this lethal
disease.Methods
Cell culture
Tongue cancer Tca8113 cells and HEK293T cells
were purchased from ATCC and maintained in DMEM
supplemented with 10% FBS, at 37°C, 5% CO2 (Gibco,
Carlsbad, CA, USA).Med19 siRNA infection
Med19 siRNA (5′-AAGGTGAAGGAGAAGCTAAGT-3′)
or negative control siRNA (5′- TTCTCCGAACGTGT
CACGT-3′) were inserted into pGCSIL-GFP lentiviral vec-
tor, respectively. The siRNA plasmids were transfected to-
gether into HEK293T cells with lentiviral helper plasmids
to generate the respective lentiviruses using Lipofectamine
2000 (Invitrogen, Grand Island, NY 14072, USA). Viral
stocks were made and used to infect tongue cancer cells.
Cells were collected for mRNA and protein levels detection
after 72 h after infection.Reverse transcription polymerase chain reaction
Total mRNA samples of tongue cancer cells were prepared
with Trizol reagent (Invitrogen, Grand Island, NY 14072,
USA) according to the manufacturer’s instructions. Sam-
ples (2.0 μg) were used as templates to perform the RT-
PCR assay using M-MLV-RTase (Promega, Madison, WI
53711, USA). The resulting cDNA was amplified by using
the SYBR-Green Master PCR Mix (Applied Biosystem,
Grand Island, NY 14072, USA) in triplicates. Real-time
PCR was performed on the TP800 qPCR System (Takara,
SW, Akron, OH 44314, USA). Primers used for real-time





Cells were lysed in 1 × SDS lysis buffer (1 M Tris-HCl pH
6.8, 2% SDS, 20% glycerol, 1 mM aprotinin, 1 mM PMSF
and 10 μg/mL leupeptin). The protein samples were
separated by electrophoresis in SDS-PAGE and then
transferred to a polyvinylidene difluoride (PVDF) mem-
brane. After blocking with Tris buffer saline (TBS)
containing 5% nonfat milk and 0.1% Tween 20 overnight,
the membrane was subsequently incubated with primary
antibodies at room temperature for 2 h or at 4°C overnight
and with secondary antibody for another 2 h, respectively.
The membrane was then developed using the ECL+plus™
Western blotting system (Amersham).
Cell proliferation assay
Tca8113 cells were infected with Med19 siRNA lenti-
virus or control lentivirus for 3 days. About 2,000 cells
were seeded into each well in 96-well plates. An MTT
cell proliferation assay was performed for 5 consecutive
days and a BrdU incorporation assay was performed at
24 h and 48 h. Results were expressed as the absorbance
at 570 nm and 490 nm, respectively.
Colony formation assay
Med19 siRNA lentivirus or mock control infected Tca8113
cells were collected 3 days after lentivirus infection. For the
plate clone forming experiment, 500 cells were mixed in
culture medium, and seeded in 6-well plates and each with
three duplicate wells. Afterward, the cells were incubated at
37°C in air with 5% CO2 and the media were renewed every
3 days. Two weeks later, the colonies were stained with
Giemsa and the colony number was statistically analyzed.
Cell cycle analysis
Lentivirus infected tongue cancer cells were fixed with
70% pre-chilled ethanol at 4°C for 1 h after 3 days of lenti-
virus infection. The fixed cells were washed and stained
with propidium iodide (PI) mixture containing 50 μg/mL
PI and 100 μg/mL ribonuclease in PBS for 45 min at 37°C.
The cells were passed through a 300-mesh nylon net be-
fore the DNA content was determined by quantitative
flow cytometry with standard optics of FACScan flow
cytometer (Becton-Dickinson FACSCalibur, San Jose,
California, USA). All the groups were performed in triplet
and statistically analyzed.
Transwell migration assay
To explore the role of Med19 in tongue cancer cells, we
performed a transwell assay in a 24-well culture plate using
the Cell Invasion Assay Kit. (Invitrogen, Grand Island, NY
14072, USA) Briefly, 1 × 104 cells from different groups
were seeded on a fibronectin-coated polycarbonate mem-
brane insert (6.5 mm in diameter with 8.0 μm pores) in a
transwell apparatus (Costar, Cambridge, MA, USA) and
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After incubation for 12 h at 37°C in a CO2 incubator,
the cells on the top surface of the insert were removed
by wiping with a cotton swab. Cells that migrated to the
bottom surface of the insert were fixed with methanol,
stained with crystal violet, and scored visually in 5 random
fields using a light microscope.
Xenograft model of tumor growth in vivo
The study protocol was approved by the institutional
ethics board of the Guanghua College of Stomatology,
Sun Yat-Sen University. All efforts were made to minimize
mice suffering. BALB/c nude mice (male, 4-6 weeks old,
20 ± 2 g) were purchased from Shanghai SLRC Experi-
mental Animal Center. (Shanghai, P.R. China) Cells
were resuspended at 2 × 107 cells/mL and an aliquot of
0.25 mL cell suspension was injected subcutaneously into
athymic nude mice. Tumor volumes were determined by
external measurements and calculated according to the
equation, V = (L × W2) × 0.52 (V = volume, L = length
and W = width) [16]. Mice were sacrificed after 22 days
and tumor weights were measured.Figure 1 Med19 shRNA leads to down-regulation of Med19 in tongue
and Med19 shRNA (si-Med19) were transduced into tongue cancer cells. (b
tongue cancer cells. (c) The protein level of Med19 was downregulated byStatistical analysis
All experiments were performed three times in triplicates.
The data were analyzed with one-way ANOVA. Differences
were considered statistically significant at P value <0.05.Results
Transduction of Med19 shRNA into human tongue
cancer cells
Recombined lentivirus expressing Med19 shRNA (si-
Med19) or negative control shRNA (si-Negative) was
transduced into human tongue cancer cells at the multi-
plicity of infection (MOI) of 100, and more than 90% of
infected cells expressed GFP as determined with fluores-
cence microscopy 3 days post-transduction (Figure 1a).
To determine the effect of RNAi on the expression of
Med19 in tongue cancer cells, the mRNA and protein
levels of Med19 were analyzed after 3 days of lentivirus in-
fection, respectively. The cells transduced with Med19
shRNA showed lower expression of Med19 mRNA and
protein than those with negative control shRNA or the
blank control cells (Figure 1b, c).cancer cells. (a) Blank Control (Control), nonsense siRNA (si-negtive)
) The mRNA level of Med19 was downregulated by Med19 shRNA in
Med19 shRNA in tongue cancer cells.
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We then detected whether Med19 shRNA affected the
proliferation ability of tongue cancer cells by MTT cell
proliferation assay and BrdU incorporation assay. As
shown in Figure 2a, the growth pattern changed visibly
from the second day to the fifth day in tongue cancer
cells. Cells treated with Med19 shRNA-expressing lenti-
virus showed lower growth rate compared with the
negative control shRNA or the blank control. To test
whether silencing of Med19 could impede cell cycle pro-
gression, the incorporation rate of a proliferative marker,
BrdU, in scrambled or Med19 siRNA-transduced cells
was measured. Consistently, the BrdU assay also showed
the growth of cells was inhibited 48 h after the cells were
treated with Med19 shRNA-expressing lentivirus com-
pared with negative control shRNA or blank controls
(Figure 2b). These results revealed that knockdown of
Med19 by shRNA in tongue cancer cells did have an in-
hibitory effect on cell growth and proliferation.
The colony formation ability of tongue cancer cells is
inhibited by Med19 shRNA
We then further analyzed the proliferation potency of
tongue cancer cells treatment with Med19 shRNA by cell
colony formation assay. The colony number of Med19
shRNA treated cells decreased from 166.0 ± 7.8 colonies/
well in the control group to 124.0 ± 4.4 colonies/well inFigure 2 The proliferation of tongue cancer cells is inhibited upon M
treated with negative control shRNA or Med19 shRNA and cultured for one
treated with Med19 shRNA or negative control shRNA. (c) Representative c
shRNA. (d) Cells treated with Med19 shRNA made less clone number comp
cell sorting (FACS) analysis of cells phase of tongue cancer cells treated wit
shRNA showed higher cell numbers at the G1 phase. Mean values are deriv
standard deviation.the Med19 shRNA lentivirus infected group in tongue
cancer cells (Figure 2c, d).The cell cycle of tongue cancer cells is inhibited by
Med19 shRNA
We then performed flow cytometry assay to detect wea-
ther Med19 shRNA affected tongue cancer cell cycle by
FACScalibur flow cytometer 72 h after transduction. The
results showed that the proportion of tongue cancer
cells in G1 phase increased significantly with the des-
crease of cells in the G2/M phase (Figure 2e, f ). Our
results thus suggested that Med19 shRNA inhibited
tongue cancer cells proliferation through modulating cell
cycle progression.The migration of tongue cancer cells is inhibited by
Med19 shRNA
To test whether tongue cancer cell migration was affected
by Med19 shRNA, a transwell assay was performed. As
showed in Figure 3a, when treated with Med19 shRNA,
tongue cancer cell migration was inhibited. The migration
rate was 31%, whereas in the Med19-knockdown group, it
was only 25% (Figure 3b, P <0.05). In this way, we could
conclude that knockdown of Med19 could inhibit cell mi-
gration of tongue cancer cells. Med19 possibly plays a cri-
tical role in the migration of tongue cancer.ed19 shRNA treatment. (a) Growth curve by MTT assay. Cells were
to five days. (b) BrdU incorporation assay was performed on cells
olony of tongue cancer cells treated with control shRNA or Med19
ared with control shRNA or blank control. (e) Fluorescence-activated
h negative control or Med19 shRNA. (f) Cells treated with Med19
ed from three independent experiments. Errors indicate
Figure 3 Med19 shRNA inhibit tongue cancer cell migration. (a) Pictures of crystal violet staining cells. (b) Med19 shRNA treated cells show a
decrease in the number of migrated cells. Mean values are derived from three independent experiments. Errors indicate standard deviation.
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inhibited by Med19 shRNA
To further explore the tumor inhibited ability of Med19
shRNA, we used a xenograft model to examine whether
Med19 shRNA inhibited tumor growth in vivo (Figure 4a).
When inoculated subcutaneously into athymus nude mice,
tongue cancer cells treated with Med19 shRNA had dra-
matically reduced tumor volumes (Figure 4b and 4c) and
tumor weights (Figure 4d) compared with blank control
cells (Control) and control negative shRNA treated withFigure 4 Med19 shRNA inhibits tongue cancer cell tumor growth in v
tumors from mice (c). (b) Med19 shRNA treated tongue cancer cells show
show lower tumor weight.cells, indicating that Med19 promotes the tumorigenesis of
tongue cancer cells.
Discussion
Tongue carcinoma is one of the most common types of
oral cancer [2], which represents the sixth most com-
mon cancer around the world [1]. Despite the improve-
ments in treatment for tough cancer, the etiology of this
disease is still unknown. With the help of lentivirus-
mediated gene silencing technique, more and more genesivo. Representative images of tongue tumor-bearing mice (a) and
smaller tumor volume. (d) Med19 shRNA treated tongue cancer cells
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in recent years. Among these cancer-related genes, many
gene expression patterns have been demonstrated to be
altered partially due to transcriptional regulation. Thus,
elucidation of critical roles of transcriptional regulators
will help us to understand the progression of tongue
carcinogenesis.
Med19 is one of the components of the Mediator com-
plex, which acts as a molecular bridge between transcrip-
tional activator and RNA polymerase II [17]. Although
Med19 has been suggested to play an important role in
many cancer types [11-15], the pathologic importance of
this molecule in tongue cancer is yet unknown. In this
study, we investigated the antitumorigenic effects of len-
tivirus-mediated transduction of Med19 shRNA into
tongue cancer cells by quantifying cellular proliferation,
tumor growth, cell cycle and migration ability. Our results
suggest that downregulation of Med19 by shRNA resulted
in inhibition of cell proliferation, colony formation and
migration ability, and induction of G0/G1 phase cell cycle
arrest. Furthermore, the antitumor effects of Med19 were
elucidated by in vivo tumorigenicity experiments. Our re-
search was the first report in which it has been demon-
strated that Med19 modulates tongue cancer cell
proliferation and migration and disruption of Med19 has
antitumorigenic effects.
The mechanism through which Med19 induced tongue
carcinogenesis is still unknown. It has been reported that
many components of the Mediator complex can directly
bind a variety of regulatory transcription factors that are
indispensible for cell growth and differentiation. For ex-
ample, MED1/TRAP220 and MED17 can bind to GATA
family membranes [18], BRCA-1 [19] and P53 [20]. Thus,
it is possible that there may be interactions between
Med19 and these cell growth transcription factors via dir-
ect or indirect binding. Udayakumar and his colleagues
have showed that the Mediator complex regulates gene
expression of Aurora-A, a centrosome kinase critical for
cell cycle progression [21]. In prostate cancer, it has been
demonstrated that the expression of CDK4 was decreased
after Med19 disruption [15]. Overall, although it is pos-
sible that Med19 like other components of the Mediator
complex, could directly or indirectly bind with transcrip-
tion factors, which are necessary for cell growth and cell
cycle progression, it is still worth working to demonstrate
the exact signaling pathway involved in the regulation of
progression in tongue cancer by Med19.
RNA interference (RNAi) is sequence-specific post-
transcriptional gene silencing by short small interfering
RNA (siRNA), which is thought to be a powerful approach
for studying gene function and gene therapy [22]. Due to
the ease of delivery, adenovirus, retrovirus, and lentivirus
are commonly used for shRNA transduction [23-25]. Len-
tiviruses are considered to be more suitable for genetherapy for their safety and life-long expression of shRNA
[26,27].Conclusions
Our results provide the evidence that lentivirus-
mediated Med19 downregulation inhibits tongue cancer
cell proliferation and tumorigenesis both in vitro and
in vivo, suggesting that disruption of Med19 by lentivirus
transduction may be a promising approach for tongue
cancer therapy.
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